News

The predominant themes observed were the presence of a specific trigger (stressful event) for fibromyalgia symptoms, fulfilling expected gender roles, a lack of support from family members, and abuse.

Themes regarding improvement experience, developing strategies for better health, and contextual factors supporting improvement were reported during the interview analysis.

Pain intensity, quality of life, and depression were significantly improved in a cohort of patients with fibromyalgia treated with THC.

The yoga-based, mind-body intervention was effective for most patients with chronic pain, with the largest effects demonstrated in areas of pain self-efficacy, pain intensity, quality of life, and most severe perceived pain.

Celastrol may regulate core target proteins to alleviate the inflammatory response.

Guselkumab was able to provide minimal disease activity improvements from baseline through week 48 in adult patients with psoriatic arthritis.

A prospective, nonrandomized trial has returned results indicating adolescents and young adults who undergo bariatric surgery experienced a decrease in bone density relative to their counterparts who opted for exercise and nutrition counseling.

Patients with unrestful sleep had significantly reduced health-related quality of life and significantly more depressive symptoms.

The risk of ischemia heart disease was significantly higher in the SLE cohort when compared with controls, with risks peaking between the 6th and 9th year post-diagnosis.

The rheumatology month in review highlights a program developed by Janssen to support health equity, the increased risks pregnant women with rheumatic diseases face, and trends in fibromyalgia management.

NHANES data presented at EULAR 2023 offer insight into trends in the risk of mortality over a time period beginning in 1988 and lasting through 2016.

While most patients were interested in an online wellness program for managing their psoriatic arthritis, barriers, such as cost and fatigue, hindered their initiation of lifestyle adaptations.

An analysis of the ORAL Surveillance trial details the efficacy of tofacitinib relative to TNF inhibition based on history of ASCVD and baseline cardiovascular risk.

Patients in the land- and water-based exercise intervention groups demonstrated greater improvements in fatigue when compared with controls.

More than 90% of respondents reported being “somewhat likely” or “very likely” to speak with an online coach ≥2 per week or spend 1 – 2 hours per week learning about lifestyle behaviors if given the opportunity.

Data presented at EULAR 2023 details the factors that matter most to patients with gout when considering the continuation or discontinuation of urate-lowering therapy after achieving clinical remission.

A modification of DAS28 was shown to more accurately represent disease activity in patients with rheumatoid arthritis and concomitant fibromyalgia.

George Karpouzas, MD, discusses the results of a study he presented at EULAR 2023 examining associations between bDMARD use and cardiovascular risk later in life.

Patients with rheumatoid arthritis and high disease activity were more likely to be diagnosed with depression and fibromyalgia when compared with those in remission.

A new-user, active comparator cohort study from EULAR 2023 suggests use of SGLT2 inhibitors could lower risk of recurrent gout flares in people with type 2 diabetes and gout compared to use of DPP-4 inhibitors.

A pair of studies presented at EULAR 2023 offer perspective on the potential for postpartum depression as well as symptoms of depression and anxiety during pregnancy among women with rheumatic disease.

A group of rheumatologists attending EULAR 2023 provide perspective on their concern regarding the potential threat posed by long COVID in patients with rheumatic disease.

An analysis of data from the phase 2 AURA-LV and phase 3 AURORA 1 trials provides new insight into the effects of voclosporin for the treatment of active lupus nephritis in patients with high proteinuria.

After 12 weeks of treatment, the median sUA levels of patients with gout were reduced from 8.6 mg/dL to 3.6 mg/dL in the AR882 75 mg cohort and 5.0 mg/dL in the AR882 50 mg group.

Results of the SELECT-AXIS 2 study supported the efficacy and safety profile of upadacitinib in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy.

Over a 3-year period, patients treated with upadacitinib reported greater disease improvements and a greater mean change from baseline when compared with those receiving adalimumab.

Response rates in the DISSOLVE I and DISSOLVE II high-dose and low-dose groups receiving SEL-212 were significantly different from the placebo group.

Patients receiving 6MP prophylaxis experienced significantly reduced incidence of arthromyalgia and Health Assessment Questionnaire worsening of 22% or increase of .25.

In patients with systemic lupus erythematosus receiving rituximab and belimumab, Black and Indo-Asian patients were less likely to obtain major clinical response.

An analysis of data from the APPLE study provides insight into the heterogeneity that exists within pediatric systemic lupus erythematosus patients.